Physician profile
James E Creek
NPI 1619091998
$6,363.38
in general payments reported to CMS, 2019-2025
29 companies · $413 in 2025
The $413 reported for 2025 was more than what 81% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $1,238 · 2021: $1,251 · 2022: $1,624 · 2023: $464 · 2024: $401 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,555.32 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,078.45 | 2019-2025 | Farxiga |
| Corcept Therapeutics | $794.40 | 2021-2025 | Korlym |
| Lilly USA, LLC | $446.10 | 2019-2023 | Jardiance, Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $406.63 | 2021-2025 | |
| Abbvie INC. | $379.19 | 2019-2025 | Vraylar, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.46 | 2019-2023 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $233.97 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Janssen Pharmaceuticals, INC | $198.24 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $131.49 | 2021-2022 | |
| Allergan, INC. | $127.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.86 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $78.57 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $70.07 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $69.85 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $56.88 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $50.48 | 2022 | |
| Pfizer INC. | $50.15 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $39.66 | 2019-2020 | |
| Dexcom, INC. | $38.64 | 2021-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.45 | 2021 | |
| Eisai INC. | $29.12 | 2020-2021 | |
| Glaxosmithkline, LLC. | $27.03 | 2022-2025 | Trelegy Ellipta |
| Amgen INC. | $21.55 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $20.35 | 2021 | |
| Abbott Laboratories | $17.92 | 2021 | |
| Smith+Nephew, INC. | $17.00 | 2023 | Collagenase Santyl |
| Ascensia Diabetes Care US INC. | $16.50 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Creek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.